October 18th 2024
The completion of a new drug application for the combination of avutometinib and defactinib in KRAS-mutant ovarian cancer is expected to be finalized with the FDA by the end of the month.
September 15th 2024
MET Inhibitor AMG-337 Shows Promise in Some Patients with Advanced Gastroesophageal Cancer
January 17th 2015Patients with advanced, MET-amplified gastroesophageal cancer had a high likelihood of response to an investigational MET inhibitor, results from a preliminary, dose-escalation trial suggested.
Read More
New York State Awards Grant for First Stem-Cell Immunotherapy Trial in Ovarian Cancer
January 16th 2015The New York State Stem Cell Science Program recently awarded a 4-year $11.9 million grant to Roswell Park Cancer Institute to fund research and development of a stem-cell based treatment for ovarian cancer.
Read More
Ovarian Suppression Lowers Risk of Recurrence in Younger, Premenopausal Breast Cancer Patients
December 12th 2014Women with HR+ breast cancer who remained premenopausal after receiving chemotherapy had a lower risk of disease recurrence when adding ovarian suppression to adjuvant exemestane or—to a lesser extent—tamoxifen, compared with standard tamoxifen alone.
Read More
Nilotinib Efficacious in Elderly Patients With Philadelphia-Positive ALL
December 8th 2014Treatment with nilotinib (Tasigna) in combination with chemotherapy elicited complete hematological remissions (CHR) in 87% of elderly patients with newly diagnosed Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL).
Read More
CAR T-Cell Therapy CTL019 Demonstrates 92% Response Rate in Pediatric ALL
December 7th 2014The anti-CD19 chimeric antigen receptor (CAR)-modified T-cell therapy CTL019 demonstrated a 92% complete response (CR) rate in pediatric patients with relapsed/refractory acute lymphoblastic leukemia (ALL).
Read More
Cirmtuzumab Blocks Ovarian Cancer Metastasis in Preclinical Study
November 18th 2014The monoclonal antibody cirmtuzumab, currently in clinical trials to treat CLL, targets ROR1 on the surface of cancerous B cells, and the agent may have a wider reach in the treatment of ovarian and other cancers.
Read More
Molecular Discoveries Yield Many Personalized Treatment Targets in Ovarian Cancer
November 7th 2014Translating current and emerging knowledge of the molecular drivers of ovarian cancer is yielding promising new insights into potential clinical targets, moving treatment away from historical paradigms in favor of more personalized therapeutic approaches.
Read More
The State of PARP Inhibitors in Ovarian Cancer: Many Agents, Many Questions
November 7th 2014PARP inhibitors represent an important class of emerging therapies for the treatment of patients with ovarian cancer and possibly other malignancies, but many scientific questions about the underlying molecular mechanisms that these agents target must be answered before they can be fully employed in clinical practice.
Read More
Trebananib Does Not Improve Survival in Ovarian Cancer
November 5th 2014A statistically significant improvement in overall survival (OS) was not seen with the combination of paclitaxel and the angiogenesis inhibitor trebananib when compared with paclitaxel alone for patients with recurrent platinum-resistant ovarian cancer.
Read More
CAR Therapy CTL019 Elicits Complete Remissions in ALL
October 20th 2014The investigational chimeric antigen receptor (CAR) therapy CTL019 elicited complete remissions in 27 of 30 pediatric and adult patients (90%) with relapsed/refractory acute lymphoblastic leukemia (ALL) in 2 pilot trials.
Read More
Novel Combination May Extend Survival in Ovarian Cancer
October 17th 2014Two agents with contrasting mechanisms of actions exert synergistic effects while limiting tumor blood supply in ovarian cancer. Patient enrollment began this month (October 2014) for a new phase 1b/2 clinical study1 to evaluate this novel combination with the VDA fosbretabulin plus pazopanib.
Read More
Lasker Winner Recommends Widespread Screening for Ovarian and Breast Cancer
September 25th 2014Mary-Claire King, PhD, the researcher who identified BRCA1's linkage to hereditary breast and ovarian cancer, was announced as the winner of the 2014 Lasker~Koshland Special Achievement Award in Medical Science.
Read More
On The Horizon for Ovarian Cancer: Potentially Promising Treatments
September 25th 2014Most patients with ovarian cancer present with bulky and metastatic disease. Surgery and platinum-based chemotherapies are the mainstay of treatment for newly diagnosed disease, but recurrence/resistance are common.
Read More
HPV Test Approvals Stress Need for Updated Screening Guidelines in Cervical Cancer
September 25th 2014The cobas HPV Test was approved in 2014 by the FDA as a primary tool for cervical cancer screening in women ≥25 years of age, highlighting the need for updated guidelines to direct the use of approved screening methods in clinical practice.
Read More
Veliparib Demonstrates Clinical Activity in Patients with BRCA-Positive Breast, Ovarian Tumors
September 6th 2014The poly (ADP-ribose) polymerase (PARP) inhibitor veliparib exhibits antitumor activity and is safe and tolerable on a continuous dosing schedule when used for the treatment of patients with BRCA-positive and BRCA-wild type tumors.
Read More